These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

865 related articles for article (PubMed ID: 25339035)

  • 1. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
    Khabaz MN
    Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
    Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS
    Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD; Nassar A; Siddiqui MT; Cohen C
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
    Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
    Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan.
    Sughayer MA; Al-Khawaja MM; Massarweh S; Al-Masri M
    Pathol Oncol Res; 2006; 12(2):83-6. PubMed ID: 16799708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM; Harhay MO; Zhang P; Ugras S
    Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India.
    Ambroise M; Ghosh M; Mallikarjuna VS; Kurian A
    Asian Pac J Cancer Prev; 2011; 12(3):625-9. PubMed ID: 21627355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of histopathologic changes and expression of biomarkers in breast carcinoma before and after neoadjuvant chemotherapy].
    Zheng S; Zhang BL; Xiao T; Zou SM; Xue LY; Luo W; Guo L; Liu XY; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2011 Jul; 40(7):465-70. PubMed ID: 22088373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
    Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
    Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
    Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
    Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subtypes of Breast Cancer in Lao P.D.R.: A Study in a Limited-Resource Setting.
    Luangxay T; Virachith S; Hando K; Vilayvong S; Xaysomphet P; Arounlangsy P; Phongsavan K; Mieno MN; Honma N; Kitagawa M; Sawabe M
    Asian Pac J Cancer Prev; 2019 Feb; 20(2):589-594. PubMed ID: 30806064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
    Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.